Liquid crystalline nanoparticles (LCNPs) have gained much attention in cancer nanomedicines due to their unique features such as high surface area, storage stability, and sustained-release profile. In the current study, a novel LCNP for co-encapsulation of BiO and hydrophilic doxorubicin (DOX) was fabricated and functionalized with folic acid (FA) to achieve efficient tumor targeting toward CT-scan imaging and chemotherapy of melanoma and . LCNPs BiO NPs were prepared using glycerol monooleate-pluronic F-127 (GMO/PF127/water). Firstly, GMO/water were homogenized to prepare LC gel. Then, the stabilizer aqueous solution (PF127/BiO/DOX) was added to the prepared LC gel and homogenized using homogenization and ultrasonication. The formulated NPs exhibited superior stability with encapsulation efficiency. High cytotoxicity and cellular internalization of the FA-BiO-DOX-NPs were observed in comparison with BiO-DOX-NPs and the free DOX in folate-receptor (FR) overexpressing cells (BF) . Moreover, ideal tumor suppression with increased survival rate were observed in tumorized mice treated with FA–BiO-DOX-NPs compared to those treated with non-targeted one. On the other hand, the CT-imaging ability of the BiO-DOX-NPs was tested inBF tumor-bearing mice. The obtained data indicated a high potential of the developed targeted theranostic FA-BiO-DOX-NPs for diagnostics and treatment of melanoma.

中文翻译：

---

合成叶酸靶向治疗诊断立方体平台，用于体外和体内将氧化铋和阿霉素共同递送至黑色素瘤

液晶纳米颗粒（LCNP）由于其高表面积、储存稳定性和缓释特性等独特特性而在癌症纳米药物中受到广泛关注。在当前的研究中，制备了一种新型 LCNP，用于 Bi2O 和亲水性阿霉素 (DOX) 的共封装，并与叶酸 (FA) 一起功能化，以实现针对黑色素瘤的 CT 扫描成像和化疗的有效肿瘤靶向。 LCNP BiO NP 使用甘油单油酸酯-pluronic F-127（GMO/PF127/水）制备。首先，将GMO/水均质化以制备LC凝胶。然后，将稳定剂水溶液（PF127/BiO/DOX）添加到制备的LC凝胶中，并使用匀浆和超声处理进行匀浆。配制的纳米颗粒表现出优异的稳定性和封装效率。与 BiO-DOX-NP 和叶酸受体 (FR) 过表达细胞 (BF) 中的游离 DOX 相比，观察到 FA-BiO-DOX-NP 的高细胞毒性和细胞内化。此外，与使用非靶向药物治疗的肿瘤小鼠相比，使用 FA-BiO-DOX-NPs 治疗的肿瘤小鼠可实现理想的肿瘤抑制效果并提高存活率。另一方面，BiO-DOX-NPs 的 CT 成像能力在 BF 荷瘤小鼠中进行了测试。获得的数据表明所开发的靶向治疗诊断 FA-BiO-DOX-NP 在诊断和治疗黑色素瘤方面具有很高的潜力。